Unlearn.AI is a developer of a platform designed to make computational clinical trials. The company's platform accelerates clinical trials by supplementing control groups with synthetic patient data generated using AI, which helps in reducing the time to develop new medicines, enabling healthcare companies to sooner provide patients in need with life-saving therapies. Creating AI to simulate biology and improve the lives of patients. Unlearn was founded by scientists, who wanted to find a new, evidence-based approach. We operate based on proprietary approaches to machine learning principles and regulatory guidances.
Enrollment challenges and timeline delays plague clinical trials.
Twintelligent RCTs™ incorporate prognostic information from Digital Twins into randomized controlled trials to enable smaller control groups while maintaining power and generating evidence suitable for supporting regulatory decisions.
Make trials more patient-centric Clinical trials with smaller control groups are more attractive to patients. Shorten enrollment timelines Twintelligent RCTs™ reach enrollment targets faster because they require fewer patients. Increase power and confidence Twintelligent RCTs™ provide reliable evidence suitable for pivotal clinical trials.
Total Funding: N/A
Funding Stage: Series B
Business Stage: Scaling Up
Market: B2B
Company Size: 51 to 100
Founded: 2017
Nov 2023
- Announcing the latest release of our Parkinson’s Disease Digital Twin Generator
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Unlearn.ai
Director of Biostatistics Research
San Francisco, California
Digital Marketing Associate
San Francisco, CA or Remote
Senior DevOps Engineer
San Francisco, California
